🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Magnesium Sulfate as an Adjuvant to Lidocaine in MPDS Trigger Point Injections Assessed by VAS and sEMG.

RecruitingNAAges 18 Years - 70 YearsAllCairo University
NCT07390851 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Two groups of patients diagnosed with Myofascial Pain Dysfunction Syndrome (MPDS) will be included in this study. One group will receive trigger point injections of lidocaine alone. The other group will receive trigger point injections of lidocaine combined with magnesium sulfate. The study aims to compare the effectiveness of both treatments in reducing pain and improving muscle function. Patients will be assessed using a pain scale (VAS) and surface electromyography (sEMG) to measure muscle activity.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age between 18 and 70 years. 2. Clinical diagnosis of Myofascial Pain Dysfunction Syndrome (MPDS). 3. Presence of active myofascial trigger points in accessible muscles (e.g., masseter, temporalis, upper trapezius). 4. Pain duration ≥ 3 months. 5. Pain intensity ≥ 4 on the Visual Analog Scale (VAS). 6. Noprior trigger point injection in the affected area within the past 3 months. 7. Ability and willingness to provide informed consent. 8. Compliance with study visits and procedures Exclusion Criteria: 1. Known allergy or hypersensitivity to Lidocaine, Magnesium Sulfate, or related agents. 2. Current use of anticoagulants or history of bleeding disorders. 3. Systemic or local infection at or near the injection site. 4. History of fibromyalgia, central pain syndromes, or cancer-related pain. 5. Major psychiatric illnesses (e.g., schizophrenia, severe depression). 6. Recent surgery or trauma to the head, neck, or upper back (\<6 months). 7. Use of analgesics (NSAIDs, opioids) within 5 days before intervention. 8. Severe systemic diseases:- Uncontrolled diabetes mellitus- Liver or kidney failure- Severe cardiovascular conditions.
💊

What it tests

  • Lidocaine 2% (preservative-free, without vasoconstrictor)
  • Lidocaine 2% + Magnesium Sulfate 10% (combination)
📍

Where

1 site
Faculty of oral and dental medicine, cairo university
Giza, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy